Extended Data Table 3 Demographics, characteristics at baseline, and outcomes of participants randomized to Descartes-08 who did and did not develop a fever in the primary efficacy (mITT) population

From: BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

  1. AChR, acetylcholine receptor; FcRn, fragment crystallizable (neonatal); LRP4, lipoprotein receptor-related protein 4; MG, myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MGFA, Myasthenia Gravis Foundation of America; mITT, modified intention-to-treat; QMG, Quantitative Myasthenia Gravis; SD standard deviation.
Back to article page